ABT News & Events

Abbott announced the FDA has approved the company's CardioMEMS Hero device - a pulmonary artery pressure reader - to support the care of people living with heart failure. The company said the reader contains new design features to help empower heart failure patients and their clinicians with the daily insights they need to detect and combat heart failure progression. Abbott will soon begin commercial release of the CardioMEMS HERO reader in the United States.

Abbott files automatic mixed securities shelf

Exact Sciences (EXAS) announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (ABT) at the special meeting of stockholders. Subject to the satisfaction or waiver of the remaining conditions to closing, the transaction is expected to close before the end of the second calendar quarter of 2026.